



Washington Prescription Drug Affordability Board
Cherry Street Plaza
626 8th Avenue SE
Olympia, WA 98501

March 18, 2026

Re: Concerns with WA PDAB and UPLs

Dear Members of the Prescription Drug Affordability Board,

On behalf of the Infusion Access Foundation, which represents patients across Washington who rely on infusion therapy to manage chronic and life-threatening conditions, we write to express our concerns with the Washington Prescription Drug Affordability Board's (PDAB) imposition of Upper Payment Limits (UPLs) on certain medications, as this policy would threaten access to essential treatments for thousands of vulnerable Washington patients.

The Infusion Access Foundation is a nonprofit advocacy organization dedicated to protecting access to infusions and injections. We support patients across all disease states and advocate for expanding access to the therapies that help patients live their best, healthiest lives. In conjunction with our grassroots advocacy work, we advocate for individual patients who face significant barriers to care.

Many of the patients we represent live with complex autoimmune diseases, neurological conditions, genetic disorders, and other serious illnesses that require regular infusion therapy to maintain their health and quality of life. Infusion providers purchase these medications upfront before seeking reimbursement from insurers. If UPLs result in reimbursement rates below the actual cost of acquiring and administering these treatments, providers may be forced to reduce services or shut down, leaving patients with limited or no access to the care they need.

For many patients, infusion therapy is not optional, it is lifesaving. Restricting access to these medications could lead to disease progression, hospitalizations, disability, and significant declines in health outcomes. Washington should be working to expand



access to high-quality, specialized care, not implementing policies that could force providers out of business and leave patients without viable treatment options. For example, addressing the practices of pharmacy benefit managers (PBMs) that increase costs for patients without meaningful improvements in quality of care may be more effective in achieving the PDAB's stated goals than imposing UPLs.

We urge you to reconsider the PDAB's current UPL-centered strategy to ensure that Washington patients can continue receiving the care they depend on. Thank you for your time and commitment to protecting patient access to essential therapies. We welcome the opportunity to discuss this critical issue further.

Sincerely,

A handwritten signature in black ink, appearing to read "Alicia B", with a long, sweeping underline.

Alicia Barron, LGSW
Executive Director
Infusion Access Foundation